The chief executive officer of FlowMetric discussed the company’s role in supporting the development of novel gene and cell therapies.
“mRNA vaccines have accelerated the pace of using viral vectors as a means of providing a therapy. Our analysis is at the cellular level, so we are looking to analyze everything from cancer mechanism of action to how new therapies interact with the immune system in terms of safety and potency.”
As gene and cell therapy companies emerge onto the pharmaceutical and biotechnology scene, more analytical support is needed to properly understand all facets of safety and efficacy of novel gene therapies. One company in this space is FlowMetric, which works with companies to analyze data for proof-of-concept studies and preclinical trials and how the immune system interacts with these new therapies.
GeneTherapyLive spoke with Renold J. Capocasale, chief executive officer and founder, FlowMetric, to learn more about the company’s role in accelerating the pace in helping companies to develop novel gene therapies and supporting preclinical operations. He also discussed the company’s work in developing novel, validated assays for companies to use as end points in a consistent way across clinical trials and potentially patient use in the future.
Capocasale believes that monitoring the immune system is a valuable way to assess different facets of therapies, such as efficacy, relevance, and safety. He detailed how the company’s analysis, on a cellular level, allows them to pinpoint therapeutics targets as well as off-target effects on other cells.